Elanco updates licence for atopic dermatitis treatment Atopica

Elanco Animal Health has announced an update to the licence for its canine atopic dermatitis treatment Atopica.

The updated licence details the need for consideration to be given to the use of other measures or treatments to control moderate to severe pruritus when initiating therapy with Atopica.

This pruritus control can be provided by anti-inflammatory doses of prednisolone, with the safety and efficacy of this combination having been confirmed in a clinical study, which is included on the updated Atopica package leaflet.

Elanco has made these changes in recognition of the importance of understanding the underlying cause of itches while treating dermatology cases in domestic animals.

Alice Laurens, dermatology marketing manager at Elanco Animal Health, said: "Dermatology cases can be difficult to treat. However, the new flexible approach and the ability to combine Atopica with prednisolone will swiftly help to control pruritus in the short term and keep the pet comfortable in the long term."

The product has been available for around a decade, with variants of the drug available for dogs and cats.